Premium
Ketoconazole increases plasma concentrations of antimalarial mefloquine in healthy human volunteers
Author(s) -
Ridtitid W.,
Wongnawa M.,
Mahatthanatrakul W.,
Raungsri N.,
Sunbhanich M.
Publication year - 2005
Publication title -
journal of clinical pharmacy and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.622
H-Index - 73
eISSN - 1365-2710
pISSN - 0269-4727
DOI - 10.1111/j.1365-2710.2005.00651.x
Subject(s) - mefloquine , ketoconazole , pharmacology , malaria , human plasma , plasma concentration , plasmodium falciparum , medicine , chemistry , immunology , chromatography , antifungal , dermatology
Summary Background: Antimalarial mefloquine has a structure related to quinine. The major metabolite of quinine is 3‐hydroxyquinine formed by cytochrome P450 3A4 (CYP3A4). Ketoconazole, a potent inhibitor of CYP3A4, is known to markedly increase plasma concentrations of various co‐administered drugs including quinine. Objective: To assess the effect of ketoconazole on plasma concentrations of mefloquine in healthy Thai male volunteers. Methods: In an open, randomized two‐phase crossover study separated by a 1‐month period, eight healthy Thai male volunteers received a single oral dose of 500 mg mefloquine alone or co‐administration with 400 mg/day ketoconazole orally for 10 days. Serial blood samples were collected at specific time points for a 56‐day period. Plasma mefloquine and mefloquine carboxylic metabolite concentrations during 56 days were measured by a modified and validated high‐performance liquid chromatographic method with UV detection. Results: Co‐administration with ketoconazole markedly increased the mean values of mefloquine AUC 0− t , t 1/2 , and C max when compared with mefloquine alone by 79% ( P < 0·001), 39% ( P < 0·05) and 64% ( P < 0·001) respectively. The AUC 0− t , and C max of mefloquine carboxylic acid metabolite were decreased by 28% ( P < 0·05) and 31% ( P < 0·05), respectively when compared with mefloquine alone. Conclusions: Co‐administration with ketoconazole increased plasma mefloquine concentrations in healthy human volunteers. One of possible mechanisms of the increase in plasma mefloquine concentrations may be the result of the inhibition of CYP3A4 by ketoconazole. In case of mefloquine is co‐administered with ketoconazole, drug–drug interactions should be recognized and the dose of mefloquine should be adjusted to maximize the therapeutic efficacy and to reduce the cost of therapy.